Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.46 |
| ▸ | TUBB | P07437 | 4/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.46 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.46 |
| ▸ | MYB | P10242 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325268 | 0.91 | TUBB4A (0.37) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4319006 | 0.88 | TUBB4A (0.44) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4321863 | 0.83 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4320423 | 0.81 | TUBB4A (0.49) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL13950361 | 0.81 | TUBB4A (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4318992 | 0.80 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4317918 | 0.80 | TUBB4A (0.47) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4318469 | 0.77 | PRKCQ (0.37) | — | |
| SCHEMBL4328634 | 0.77 | PRKCQ (0.31) | — | |
| SCHEMBL4324610 | 0.77 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | claimed |
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-08-11 | — | — | US | claimed |
| EP-1513515-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-16 | — | — | EP | claimed |
| WO-2003096982-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-08-11 | — | — | US | disclosed |
| EP-1513515-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003096982-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP10 | TUBB4A 1138/4885TUBB 2304/4885TUBA3C 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.